F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comPanacea Biotec Ltd, one of India’s leading biotechnology and pharmaceutical companies, is known for its strong portfolio in vaccines, biosimilars, and specialty pharmaceuticals. With its focus on research-driven healthcare solutions and expanding global reach, the company has remained an interesting pick in the stock market. In this article, we will analyze Panacea Biotec’s business, financial standing, shareholding pattern, and projected share price targets from 2025 to 2030.
Let’s explore Panacea Biotec’s present situation and its future growth prospects.
| Detail | Value |
|---|---|
| Current Price (Open) | ₹403.30 |
| Previous Close | ₹403.40 |
| Day's High | ₹403.90 |
| Day's Low | ₹388.70 |
| 52-Week High | ₹581.90 |
| 52-Week Low | ₹220.00 |
| Market Capitalization | ₹2,424 Cr |
| VWAP | ₹395.04 |
| Beta (Volatility) | 0.87 |
| Face Value | ₹1 |
| Book Value per Share | ₹135.98 |
| Volume | 1,09,683 |
| Value (Lacs) | ₹434.18 |
| UC Limit | ₹484.05 |
| LC Limit | ₹322.75 |
| All-Time High | ₹581.90 |
| All-Time Low | ₹22.50 |
| 20D Avg Volume | 1,98,843 |
| 20D Avg Delivery (%) | 44.69 |
Founded in 1984, Panacea Biotec has emerged as a trusted pharmaceutical brand in India and abroad. The company manufactures vaccines, biosimilars, and innovative medicines addressing global healthcare needs. It has partnered with global organizations like UNICEF and WHO to supply vaccines across the world.
Strong vaccine portfolio and partnerships with international health agencies.
Rising demand for affordable biosimilars and specialty drugs.
Focused on R&D, with pipeline products under development.
Market presence across more than 30 countries.
Moderate beta (0.87), indicating relatively low volatility.
| Investor Type | Holding (%) |
|---|---|
| Promoters | 72.48% |
| Retail & Others | 25.22% |
| Other Domestic Institutions | 1.52% |
| Foreign Institutions | 0.78% |
This strong promoter holding reflects confidence in the company’s long-term vision, while retail participation remains significant.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | 410 | 440 |
| 2026 | 460 | 510 |
| 2027 | 520 | 580 |
| 2028 | 590 | 660 |
| 2029 | 670 | 740 |
| 2030 | 750 | 820 |
These projections are based on financial performance, expansion in exports, product pipeline, EPS growth, and global pharmaceutical industry trends.
By 2025, Panacea Biotec is expected to maintain steady growth with its vaccine exports and biosimilars demand.
Investment Advice: Good time for SIP investors to accumulate during market corrections.
Expansion in international markets and higher revenue from biosimilars may drive stock growth.
Investment Advice: Hold for medium to long-term gains.
By 2027, Panacea may benefit from product launches and rising healthcare demand.
Investment Advice: Reinvest dividends; pharma remains a defensive sector.
Growth in exports, especially vaccines, could push prices higher.
Investment Advice: Suitable for long-term investors seeking stability.
Consistent profits and higher R&D investments are likely to strengthen valuation.
Investment Advice: Continue holding as part of a diversified portfolio.
By 2030, Panacea Biotec may solidify itself as a global healthcare player.
Investment Advice: Strong candidate for wealth creation in the long run.
Yes. Panacea Biotec has strong fundamentals, global partnerships, and a growing presence in the vaccine and biosimilar space. It has shown resilience and steady performance over the years.
Strong promoter holding (72.48%).
Growing vaccine demand globally.
Expanding biosimilars pipeline.
Consistent improvement in book value.
Regulatory hurdles in international markets.
Dependency on government contracts and approvals.
Volatility in raw material costs.
Panacea Biotec Ltd is a promising stock in the pharmaceutical sector. With a current market price of around ₹403.30 and a market cap of ₹2,424 Cr, the company is well-positioned for long-term growth. By 2030, the share price target is estimated to reach between ₹750 and ₹820, making it an attractive option for long-term investors.
Investors seeking stability and growth in the healthcare space may find Panacea Biotec a strong addition to their portfolio.
1. What is the current share price of Panacea Biotec?
The current price is around ₹403.30 (as of August 2025).
2. Is Panacea Biotec a good buy right now?
Yes, for long-term investors focusing on pharma and healthcare growth.
3. What is the 2025 target price of Panacea Biotec?
The expected target is ₹410 – ₹440.
4. What will be the target price of Panacea Biotec in 2030?
By 2030, the stock may reach ₹750 – ₹820.
5. What is the 52-week high and low of Panacea Biotec?
52-week high: ₹581.90, 52-week low: ₹220.00.
6. What is Panacea Biotec’s shareholding pattern?
Promoters: 72.48%, Retail: 25.22%, Institutions: ~2.3%.
7. Why is Panacea Biotec stock in focus?
Because of its vaccine exports, biosimilar portfolio, and rising healthcare demand globally.
Disclaimer: This article is for educational purposes only and not financial advice. Please consult a certified financial advisor before investing.
Register & Login